Champions Oncology, Inc.

CSBR

US15870P3073

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 08/06/2024 am IST			5-day change	1st Jan Change
4.6 ^USD	-1.08%		+1.55%	-18.15%

04/06	Champions Oncology, Inc and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development	CI
15/03	Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	CI

James J. McGorry Resigns as the Executive Vice President and General Manager, Translational Oncology Solutions of Champions Oncology, Inc

July 24, 2015 at 01:21 am IST

On July 2, 2015, James J. McGorry, the executive vice president and general manager, Translational Oncology Solutions of Champions Oncology, Inc. resigned from the company.

Latest news about Champions Oncology, Inc.

Champions Oncology, Inc and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development	04/06	CI
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	15/03	CI
Craig-Hallum Downgrades Champions Oncology to Hold From Buy	13/03	MT
Champions Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	13/03	CI
Transcript : Champions Oncology, Inc., Q3 2024 Earnings Call, Mar 12, 2024	13/03
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	14/12	CI
Craig Hallum Trims Champions Oncology Price target to $9 From $10, Maintains Buy Rating	13/12	MT
Transcript : Champions Oncology, Inc., Q2 2024 Earnings Call, Dec 12, 2023	13/12
Champions Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	13/12	CI
MORNING BID AMERICAS-Disinflation station	12/12	RE
North American Morning Briefing : Traders Eye -2-	12/12	DJ
Champions Oncology, Inc. Appoints Brady Davis as President	17/23/17	CI
Roth MKM Adjusts Price Target on Champions Oncology to $7.50 From $9, Maintains Buy Rating	22/23/22	MT
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	14/23/14	CI
Transcript : Champions Oncology, Inc., Q1 2024 Earnings Call, Sep 13, 2023	14/23/14
Champions Oncology, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	14/23/14	CI
Champions Oncology Enters Multiyear Deal With BioVolume to Better Evaluate Cancer Studies	01/23/01	MT
Champions Oncology, Inc. Announces Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies	01/23/01	CI
Transcript : Champions Oncology, Inc., Q4 2023 Earnings Call, Jul 24, 2023	25/23/25
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	25/23/25	CI
Champions Oncology, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	25/23/25	CI
Champions Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended April 30, 2023	25/23/25	CI
Champions Oncology Forms Therapeutic Discovery Platform Unit Corellia AI	18/23/18	MT
Champions Oncology, Inc. announces an Equity Buyback for $5 million worth of its shares.	05/23/05	CI
Champions Oncology, Inc. authorizes a Buyback Plan.	29/23/29	CI

Chart Champions Oncology, Inc.

Duration

Period

More charts

Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Companyâs TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.

Sector

Biotechnology & Medical Research

Calendar

18/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.6 USD

Average target price

6 USD

Spread / Average Target

+30.43%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHAMPIONS ONCOLOGY, INC.	-18.15%	62.53M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research

Champions Oncology, Inc.

Equities

CSBR

US15870P3073

Biotechnology & Medical Research

James J. McGorry Resigns as the Executive Vice President and General Manager, Translational Oncology Solutions of Champions Oncology, Inc

Latest news about Champions Oncology, Inc.

Chart Champions Oncology, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research